NO20092604L - VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament. - Google Patents
VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament.Info
- Publication number
- NO20092604L NO20092604L NO20092604A NO20092604A NO20092604L NO 20092604 L NO20092604 L NO 20092604L NO 20092604 A NO20092604 A NO 20092604A NO 20092604 A NO20092604 A NO 20092604A NO 20092604 L NO20092604 L NO 20092604L
- Authority
- NO
- Norway
- Prior art keywords
- cancer
- vegf
- preventing
- antigen
- never
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Abstract
Det er beskrevet heri fremgangsmåter til å behandle godartet, precancerøs eller ikke-metastatiske tumorer ved å bruke en anti-VEGF-spesifikk antagonist. I tillegg er det beskrevet fremgangsmåter til å behandle et individ med risiko for å utvikle godartet, precancerøs eller ikke-metastatiske tumorer ved å bruke en anti-VEGF-spesifikk antagonist. I tillegg er det beskrevet fremgangsmåter til å behandle eller forhindre tilbakefall av en tumor ved å bruke en anti-VEGF-spesifikk antagonist så vel som anvendelse av VEGF-spesifikke antagonister i neoadjuvans og adjuvans kreftterapi.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87074106P | 2006-12-19 | 2006-12-19 | |
| US87074506P | 2006-12-19 | 2006-12-19 | |
| US87726706P | 2006-12-27 | 2006-12-27 | |
| US91963807P | 2007-03-22 | 2007-03-22 | |
| US95838407P | 2007-07-05 | 2007-07-05 | |
| US98939707P | 2007-11-20 | 2007-11-20 | |
| PCT/US2007/088000 WO2008077077A2 (en) | 2006-12-19 | 2007-12-18 | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20092604L true NO20092604L (no) | 2009-09-18 |
Family
ID=39323719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20092604A NO20092604L (no) | 2006-12-19 | 2009-07-08 | VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament. |
Country Status (28)
| Country | Link |
|---|---|
| US (6) | US20080248033A1 (no) |
| EP (2) | EP3095455A1 (no) |
| JP (4) | JP2010513566A (no) |
| KR (5) | KR20150097813A (no) |
| CN (1) | CN103143017A (no) |
| AR (1) | AR064458A1 (no) |
| AU (1) | AU2007333735A1 (no) |
| BR (1) | BRPI0720552A2 (no) |
| CA (1) | CA2671734A1 (no) |
| CO (1) | CO6210829A2 (no) |
| CR (1) | CR10940A (no) |
| DK (1) | DK2101807T3 (no) |
| EC (1) | ECSP099523A (no) |
| ES (1) | ES2582656T3 (no) |
| HK (1) | HK1133210A1 (no) |
| HU (1) | HUE029445T2 (no) |
| IL (1) | IL238913A0 (no) |
| MA (1) | MA31150B1 (no) |
| MX (1) | MX2009006779A (no) |
| MY (1) | MY183404A (no) |
| NO (1) | NO20092604L (no) |
| NZ (1) | NZ578472A (no) |
| PL (1) | PL2101807T3 (no) |
| RU (1) | RU2013129450A (no) |
| SG (2) | SG10201503407WA (no) |
| SI (1) | SI2101807T1 (no) |
| TW (2) | TW200831538A (no) |
| WO (1) | WO2008077077A2 (no) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2562188A3 (en) | 2006-09-29 | 2013-03-06 | OncoMed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-ｖｅｇｆ抗體 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| KR102095257B1 (ko) | 2008-06-25 | 2020-04-01 | 노바르티스 아게 | Ｖｅｇｆ를 억제하는 안정하고 가용성인 항체 |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| ES2611337T3 (es) * | 2008-11-22 | 2017-05-08 | F. Hoffmann-La Roche Ag | Uso de anticuerpo anti-VEGF en combinación con quimioterapia para tratar cáncer de mama |
| EP2393513B1 (en) * | 2009-02-06 | 2016-10-19 | The General Hospital Corporation | Methods of treating vascular lesions |
| PE20120591A1 (es) | 2009-04-02 | 2012-05-23 | Roche Glycart Ag | Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla |
| AU2010234031B2 (en) | 2009-04-07 | 2015-10-01 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| SG175289A1 (en) * | 2009-04-20 | 2011-11-28 | Genentech Inc | Adjuvant cancer therapy |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| MX2012003396A (es) | 2009-09-16 | 2012-04-10 | Genentech Inc | Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos. |
| ES2575152T3 (es) | 2009-10-16 | 2016-06-24 | Oncomed Pharmaceuticals, Inc. | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores |
| WO2011094716A1 (en) * | 2010-02-01 | 2011-08-04 | Cedars-Sinai Medical Center | Use of tyrosine kinase inhibitors for treatment of prolactinoma |
| US9387211B2 (en) | 2010-02-01 | 2016-07-12 | Cedars-Sinai Medical Center | Methods for treatment of Cushing'S disease and hypercortisolism using gefitinib |
| US9427429B2 (en) | 2010-03-01 | 2016-08-30 | Tau Therapeutics Llc | Cancer diagnosis and imaging |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
| US20120100166A1 (en) | 2010-07-15 | 2012-04-26 | Zyngenia, Inc. | Ang-2 Binding Complexes and Uses Thereof |
| EP2596364B1 (en) * | 2010-07-19 | 2015-12-16 | F.Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
| RU2013110875A (ru) | 2010-08-24 | 2014-09-27 | Ф.Хоффманн-Ля Рош Аг | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| RU2607038C2 (ru) | 2011-02-28 | 2017-01-10 | Ф. Хоффманн-Ля Рош Аг | Антигенсвязывающие белки |
| CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
| US20140219999A1 (en) * | 2011-04-01 | 2014-08-07 | The Trustees Of The University Of Pennsylvania | Treatment of colon cancer using complement inhibitors |
| US9255927B2 (en) | 2011-05-05 | 2016-02-09 | Duke University | Methods of developing a prognosis for pancreatic cancer and predicting responsiveness to cancer therapeutics |
| EP2714738B1 (en) | 2011-05-24 | 2018-10-10 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| SG11201400526TA (en) * | 2011-09-12 | 2014-04-28 | Tau Therapeutics Llc | Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells |
| HUE042192T2 (hu) | 2011-09-23 | 2019-06-28 | Oncomed Pharm Inc | VEGF/DLL4-kötõ ágensek és alkalmazásaik |
| US20130142796A1 (en) * | 2011-12-05 | 2013-06-06 | Subhransu Ray | Treatment for angiogenic disorders |
| EP2812357B1 (en) | 2012-02-10 | 2020-11-04 | F.Hoffmann-La Roche Ag | Single-chain antibodies and other heteromultimers |
| KR20150030744A (ko) | 2012-06-27 | 2015-03-20 | 에프. 호프만-라 로슈 아게 | 표적에 특이적으로 결합하는 하나 이상의 결합 단위를 포함하는 항체 Ｆｃ－영역 접합체의 제조 방법 및 그의 용도 |
| KR20150023889A (ko) | 2012-06-27 | 2015-03-05 | 에프. 호프만-라 로슈 아게 | 2 개 이상의 상이한 결합 단위를 함유하는 맞춤-제작된 고도로 선별적이고 다중-특이적인 표적화 단위의 선별 및 제조 방법 및 이의 용도 |
| KR101774121B1 (ko) | 2012-07-13 | 2017-09-01 | 로슈 글리카트 아게 | 이중특이적 항-vegf/항-ang-2 항체 및 안 혈관 질환의 치료에 있어서 이의 용도 |
| WO2014071018A1 (en) | 2012-10-31 | 2014-05-08 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a dll4 antagonist |
| JP6445451B2 (ja) | 2012-12-03 | 2018-12-26 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | ネオアジュバントベバシズマブを用いた化学療法に対する予測結果の評価 |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| CA2922912A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
| AU2015338974B2 (en) | 2014-10-31 | 2021-08-26 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| EP3227332B1 (en) | 2014-12-03 | 2019-11-06 | F.Hoffmann-La Roche Ag | Multispecific antibodies |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| AU2016381656A1 (en) * | 2015-12-30 | 2018-07-12 | Visiongate, Inc. | System and method for automated detection and monitoring of dysplasia and administration of chemoprevention |
| WO2017201166A1 (en) * | 2016-05-17 | 2017-11-23 | Duke University | Methods of predicting responsiveness of a cancer to a vegf targeting agent and methods of prognosing and treating cancer |
| KR20200090927A (ko) * | 2017-12-19 | 2020-07-29 | 아카우오스, 인크. | 내이에 대한 치료적 항체의 aav-매개 전달 |
| US11026649B2 (en) * | 2018-06-25 | 2021-06-08 | Siemens Medical Solutions Usa, Inc. | Method and system for determining tumor burden in medical images |
| WO2020171777A1 (en) * | 2019-02-18 | 2020-08-27 | Agency For Science, Technology And Research | A membrane-bound fit-1 decoy and uses thereof |
| TW202110431A (zh) * | 2019-05-17 | 2021-03-16 | 美商癌症預防製藥股份有限公司 | 治療家族性腺瘤性瘜肉症之方法 |
| CN112773852A (zh) * | 2021-03-16 | 2021-05-11 | 宁夏医科大学 | 一种对细胞有保护作用的中草药组合物的制备工艺 |
| CN113512589B (zh) * | 2021-07-14 | 2023-03-10 | 复旦大学附属中山医院 | Prune1基因检测在多发性骨髓瘤患者预后中的应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4675187A (en) | 1983-05-16 | 1987-06-23 | Bristol-Myers Company | BBM-1675, a new antibiotic complex |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP1493825A3 (en) | 1990-06-11 | 2005-02-09 | Gilead Sciences, Inc. | Method for producing nucleic acid ligands |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| US20030206899A1 (en) | 1991-03-29 | 2003-11-06 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| US6582959B2 (en) | 1991-03-29 | 2003-06-24 | Genentech, Inc. | Antibodies to vascular endothelial cell growth factor |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| EP1975181B1 (en) | 1992-10-28 | 2011-02-16 | Genentech, Inc. | Use of vascular endothelial cell growth factor antagonists |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| IL117645A (en) | 1995-03-30 | 2005-08-31 | Genentech Inc | Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| WO1997033551A2 (en) | 1996-03-15 | 1997-09-18 | Millennium Pharmaceuticals | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| ES2361267T3 (es) | 1997-04-07 | 2011-06-15 | Genentech Inc. | Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria. |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| US20030114407A1 (en) | 2001-12-06 | 2003-06-19 | Monia Brett P. | Antisense modulation of G protein-coupled receptor ETBR-LP-2 expression |
| EP2386574A3 (en) | 1999-01-15 | 2012-06-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0010017A (pt) | 1999-04-28 | 2002-06-11 | Univ Texas | Composições e processos para o tratamento de câncer por inibição seletiva de vegf |
| US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
| JP2001072587A (ja) * | 1999-07-01 | 2001-03-21 | Taisho Pharmaceut Co Ltd | Ｖｅｇｆ受容体拮抗剤 |
| ATE428719T1 (de) | 1999-07-29 | 2009-05-15 | Gilead Sciences Inc | Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors |
| ES2270893T3 (es) | 1999-12-24 | 2007-04-16 | Genentech, Inc. | Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos. |
| US7342016B2 (en) * | 2000-08-30 | 2008-03-11 | Schering Corporation | Farnesyl protein transferase inhibitors as antitumor agents |
| EP3569610A3 (en) | 2000-12-12 | 2020-03-18 | Medlmmune, LLC | Molecules with extended half lives, compositions and uses thereof |
| RS20050885A (sr) * | 2003-05-30 | 2008-04-04 | Genentech | Lečenje sa anti-vegf antitelima |
| SI1636593T1 (sl) | 2003-06-06 | 2009-08-31 | Genentech Inc | Moduliranje interakcije med beta-verigo HGF in c-met |
| US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| US20050044853A1 (en) * | 2003-09-02 | 2005-03-03 | Kazutora Yoshino | Ecology system |
| AU2005254058A1 (en) * | 2004-06-10 | 2005-12-29 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for the treatment of human cancer |
| US20060009360A1 (en) | 2004-06-25 | 2006-01-12 | Robert Pifer | New adjuvant composition |
| AU2005269716B2 (en) * | 2004-07-20 | 2011-01-27 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
-
2007
- 2007-12-18 PL PL07869456.9T patent/PL2101807T3/pl unknown
- 2007-12-18 JP JP2009543152A patent/JP2010513566A/ja active Pending
- 2007-12-18 BR BRPI0720552-0A2A patent/BRPI0720552A2/pt not_active Application Discontinuation
- 2007-12-18 EP EP16164548.6A patent/EP3095455A1/en not_active Withdrawn
- 2007-12-18 NZ NZ578472A patent/NZ578472A/en not_active IP Right Cessation
- 2007-12-18 HU HUE07869456A patent/HUE029445T2/en unknown
- 2007-12-18 MY MYPI20092394A patent/MY183404A/en unknown
- 2007-12-18 DK DK07869456.9T patent/DK2101807T3/en active
- 2007-12-18 EP EP07869456.9A patent/EP2101807B1/en not_active Not-in-force
- 2007-12-18 TW TW096148476A patent/TW200831538A/zh unknown
- 2007-12-18 KR KR1020157021564A patent/KR20150097813A/ko not_active Application Discontinuation
- 2007-12-18 MX MX2009006779A patent/MX2009006779A/es unknown
- 2007-12-18 TW TW103140661A patent/TWI577695B/zh not_active IP Right Cessation
- 2007-12-18 KR KR1020147002744A patent/KR20140031996A/ko not_active Application Discontinuation
- 2007-12-18 AU AU2007333735A patent/AU2007333735A1/en not_active Abandoned
- 2007-12-18 ES ES07869456.9T patent/ES2582656T3/es active Active
- 2007-12-18 SG SG10201503407WA patent/SG10201503407WA/en unknown
- 2007-12-18 KR KR1020097014282A patent/KR20090097188A/ko not_active Application Discontinuation
- 2007-12-18 SI SI200731805A patent/SI2101807T1/sl unknown
- 2007-12-18 KR KR1020137007960A patent/KR20130060309A/ko not_active Application Discontinuation
- 2007-12-18 SG SG2011080801A patent/SG176448A1/en unknown
- 2007-12-18 KR KR1020147032041A patent/KR20140148491A/ko not_active Application Discontinuation
- 2007-12-18 CN CN2012100915514A patent/CN103143017A/zh active Pending
- 2007-12-18 WO PCT/US2007/088000 patent/WO2008077077A2/en active Application Filing
- 2007-12-18 CA CA002671734A patent/CA2671734A1/en not_active Abandoned
- 2007-12-18 US US12/002,605 patent/US20080248033A1/en not_active Abandoned
- 2007-12-19 AR ARP070105735A patent/AR064458A1/es unknown
-
2009
- 2009-07-08 NO NO20092604A patent/NO20092604L/no not_active Application Discontinuation
- 2009-07-09 MA MA32085A patent/MA31150B1/fr unknown
- 2009-07-17 CO CO09074843A patent/CO6210829A2/es not_active Application Discontinuation
- 2009-07-17 CR CR10940A patent/CR10940A/es unknown
- 2009-07-17 EC EC2009009523A patent/ECSP099523A/es unknown
-
2010
- 2010-01-27 HK HK10100860.5A patent/HK1133210A1/zh not_active IP Right Cessation
- 2010-06-29 US US12/826,001 patent/US20110052576A1/en not_active Abandoned
-
2012
- 2012-02-22 US US13/402,645 patent/US20120148584A1/en not_active Abandoned
-
2013
- 2013-05-17 JP JP2013104923A patent/JP2013189452A/ja active Pending
- 2013-06-27 RU RU2013129450/15A patent/RU2013129450A/ru not_active Application Discontinuation
- 2013-07-26 US US13/952,259 patent/US20140178363A1/en not_active Abandoned
-
2015
- 2015-01-15 JP JP2015005626A patent/JP2015110609A/ja not_active Withdrawn
- 2015-05-20 IL IL238913A patent/IL238913A0/en unknown
- 2015-06-26 US US14/752,284 patent/US20160108116A1/en not_active Abandoned
-
2017
- 2017-08-15 US US15/677,804 patent/US20180208647A1/en not_active Abandoned
- 2017-10-13 JP JP2017199344A patent/JP2018052939A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20092604L (no) | VEGF-spesifikke antagonister antistoff eller antigenbindende fragmenter derav for anvendelse i en fremgangsmåte for å redusere eller forhindre forekomst av kreft hos et individ som aldri har hatt klinisk detekterbar kreft, samt anvendelse derav for fremstilling av et medikament. | |
| NO20060398L (no) | Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft | |
| NO20082683L (no) | Neuroendokrin tumorbehandling | |
| NO20084546L (no) | Diagnostikk og behandlinger for tumorer | |
| WO2010009342A3 (en) | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors | |
| NO20066056L (no) | Behandling med Gemcitabin og en EGFR-inhibitor | |
| NO20074366L (no) | Fremgangsmate for a behandle gefitmibresistent kreft | |
| NO20070514L (no) | Pyrrolotriazin kinase inhibitorer | |
| BRPI0512500A (pt) | tratamento ou condições envolvendo desmielinação | |
| NO20050528L (no) | Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft | |
| NO20066054L (no) | behandling med cisplatin og en EGFR-inhibitor | |
| NO20084374L (no) | Imidazoltiazolforbindelser for behandling av sykdom | |
| SG169382A1 (en) | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products | |
| NO20090623L (no) | Forbindelser for behandling av proliferative lidelser | |
| NO20090450L (no) | Tumorterapi med at anti-VEGF antistoff | |
| NO20092725L (no) | Quinazoliner for PDK1 inhibering | |
| NO20091635L (no) | Sammensetninger og fremgangsmater for diagnostisering og behandling av kreft | |
| CL2008000020A1 (es) | Compuestos derivados de 2,4-dianilinopirimidinas sustituidas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y tumores malignos. | |
| NZ584787A (en) | Inhibition of angiogenesis with a Bv8 antagonist | |
| WO2008072777A3 (en) | Ttk as tumor marker and therapeutic target for lung cancer | |
| NO20072179L (no) | Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer | |
| NO20066080L (no) | Behandling med irinotecan (CPT-11) og en AGFR-inhibitor | |
| WO2007016338A3 (en) | Use of chk2 kinase inhibitors for cancer treatment | |
| WO2009015050A3 (en) | Gene expression profile for predicting ovarian cancer patient survival | |
| Diaz-Miqueli et al. | Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CREP | Change of representative |
Representative=s name: TANDBERGS PATENTKONTOR AS, POSTBOKS 1570 VIKA, 011 |
|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |